If you are wondering whether Teva Pharmaceutical Industries' current share price lines up with its underlying worth, you are in the right place to unpack what the market might be pricing in. Teva's ...
After a whirlwind of conference news Monday, we're doing it all over again with Day 2 of the J.P. Morgan Healthcare ...
Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 million, to support Teva's anti-IL-15 candidate, TEV-'408 TE ...
Richard Francis, Teva's President and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 8:15 A.M. Pacific Time (11:15 A.M. Eastern Time)TEL AVIV, ...
Detailed price information for Teva Pharmaceutical Industries ADR (TEVA-N) from The Globe and Mail including charting and trades.
Teva Pharmaceutical Industries Limited (NYSE:TEVA) is one of the best performing pharma stocks in 2025. Truist lifted the ...
The FDA approved Scinopharm's glatiramer acetate injection, a generic version of Copaxone, to treat multiple sclerosis.
The Skinny Labels, Big Savings Act was introduced on January 9 in an effort to provide “a statutory safe harbor from patent ...
Health Canada is currently considering nine submissions from other drug companies to make generic semaglutide.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback